[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[S. 5297 Introduced in Senate (IS)]

<DOC>






119th CONGRESS
  2d Session
                                S. 5297

  To require the Administrator of the Centers for Medicare & Medicaid 
     Services to submit a report regarding the use of coverage and 
      reimbursement authorities to protect the markets for active 
         pharmaceutical ingredients and key staring materials.


_______________________________________________________________________


                   IN THE SENATE OF THE UNITED STATES

                             August 6, 2026

   Mr. Schiff (for himself and Mr. Scott of Florida) introduced the 
 following bill; which was read twice and referred to the Committee on 
                                Finance

_______________________________________________________________________

                                 A BILL


 
  To require the Administrator of the Centers for Medicare & Medicaid 
     Services to submit a report regarding the use of coverage and 
      reimbursement authorities to protect the markets for active 
         pharmaceutical ingredients and key staring materials.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``American Pharmaceutical Security 
Act''.

SEC. 2. REPORT ON MARKETS FOR API AND KEY STARTING MATERIALS.

    (a) In General.--Not later than 1 year after the date of enactment 
of this Act, the Administrator of the Centers for Medicare & Medicaid 
Services (referred to in this section as the ``Administrator'') shall 
submit to Congress a report on its findings and policy recommendations 
regarding the use of coverage and reimbursement authorities to protect 
the markets of the United States and its allies for active 
pharmaceutical ingredients and key starting materials and reduce direct 
and indirect dependence on foreign adversaries (as described in section 
791.4 of title 15, Code of Federal Regulations (or any successor 
regulations)) for such ingredients and materials.
    (b) Contents.--The report under subsection (a)--
            (1) may include--
                    (A) recommendations for price floor commitments in 
                support of domestic manufacturing of active 
                pharmaceutical ingredients and key starting materials 
                to protect investments in the domestic markets of such 
                ingredients and materials against nonmarket practices 
                and price manipulation; and
                    (B) recommendations that would prioritize 
                domestically manufactured active pharmaceutical 
                ingredients and key starting materials over foreign 
                manufactured active pharmaceutical ingredients and key 
                starting materials when a domestic source for the 
                applicable ingredient or material exists; and
            (2) shall identify any existing gaps in data and 
        information related to the origin and ownership of active 
        pharmaceutical ingredients and key starting materials that the 
        Administrator would need to implement the recommendations 
        included in the report.
                                 <all>